Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia

(May 20, 2019)

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable... Continue Reading


Zytig Treatment Prolongs Survival in Advanced Prostate Cancer

(May 7, 2019)

Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC) About... Continue Reading


FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation

(May 7, 2019)

On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at... Continue Reading


Subcutaneous Herceptin Effective Option for Women With HER2-positive Breast Cancer

(May 6, 2019)

One year of IV Herceptin (trastuzumab) is the standard of care for women with HER2-positive early stage breast cancer (ESBC). Doctors from Germany have confirmed that Herceptin can safely be administered subcutaneously without compromising effectiveness... Continue Reading


Ice Chips May Be The Easiset Way to Reduce Mucositis From Cancer Treatment

(May 3, 2019)

A new study in the April 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network reports that oral cryotherapy reduce mucositis related side effects. Ice chips or “cryotherapy” has long been used to reduce the intensity of mouth... Continue Reading


ASCO Guideline: Oxaliplatin Adjuvant Therapy for Stage III Colon Cancer May Be Reduced in Select Patients

(May 1, 2019)

The American Society of Clinical Oncology (ASCO) has released a new guideline that states that patients with clinically low-risk stage III colon cancer should have the option of receiving 3 months of adjuvant oxaliplatin-based chemotherapy. For patients... Continue Reading


37,000 Patient Meta-Analyses Confirms Benefit of Dose Dense Therapy for Treatment of Early Stage Breast Cancer

(April 30, 2019)

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of women with HER2-negative early stage breast cancer... Continue Reading


FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma

(April 16, 2019)

granted accelerated approval to Balversa (erdafitinib) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy,... Continue Reading


Most women can get mammograms every other year starting at age 50

(April 11, 2019)

Women who are not at high risk for breast cancer can wait to start getting mammograms until age 50 and be screened every other year, according to new guidelines from the American College of Physicians. Women at high risk for breast cancer are those with... Continue Reading


Dose Intense Chemotherapy Improves Survival When Used For Treatment of Early Stage Breast Cancer

(April 8, 2019)

Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer. The analyses was performed by British physicians in... Continue Reading


CD40 Combination Therapy Can Shrink Pancreatic Tumors

(April 4, 2019)

A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients – 20 out of 24 as of an interim analysis of the phase 1b trial data. The early findings provide hope that this strategy... Continue Reading


GARNET Study Suggets Dostarlimab Promising for Uterine/Endometrial Cancer

(March 28, 2019)

An early phase clinical trial evaluating dostarlimab in women with recurrent or advanced endometrial cancer appears promising.  These data were presented at the 2019 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Honolulu,... Continue Reading


Next Page »